Catalyst
Slingshot members are tracking this event:
Top-Line Data Expected in Q4 2017 for Aimmune's (AIMT) Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 20, 2018
Occurred Source:
http://ir.aimmune.com/news-releases/news-release-details/aimmune-therapeutics-pivotal-phase-3-palisade-trial-ar101-meets
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Palisade, Top-line Data, Peanut Allergies
